4basebio (LON:4BB) Shares Down 0.4% - Time to Sell?

Key Points

• 4basebio PLC shares fell by 0.4%, trading at GBX 881.50 ($11.86), with a significant drop in volume at only 135 shares traded compared to the average of 1,143 shares.
• The company has a market capitalization of £112.92 million and a troubling price-to-earnings ratio of -1,130.13, indicating potential financial distress.
• 4basebio reported a quarterly earnings per share (EPS) of GBX (0.94), with analysts predicting a full-year EPS of -3.43, highlighting ongoing challenges for the company.

4basebio PLC (LON:4BB - Get Free Report) traded down 0.4% during mid-day trading on Monday . The stock traded as low as GBX 881.50 ($11.86) and last traded at GBX 881.50 ($11.86). 135 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 1,143 shares. The stock had previously closed at GBX 885 ($11.91).

4basebio Stock Performance

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm has a 50-day moving average of GBX 962.20 and a 200-day moving average of GBX 1,067.45. The stock has a market capitalization of £112.92 million, a price-to-earnings ratio of -1,130.13 and a beta of 1.09.

4basebio (LON:4BB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 27th. The company reported GBX (0.94) EPS for the quarter. As a group, sell-side analysts predict that 4basebio PLC will post -3.43 earnings per share for the current year.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.